news
AstraZeneca to invest $360 million in Irish manufacturing facility
The next-generation active pharmaceutical ingredient manufacturing facility should meet the needs for AstraZeneca’s new medicines pipeline.
List view / Grid view
Sustainability
news
GSK invests £50 million in renewable energy for Climate Week NYC
GSK announced multi-million renewable energy investment and low carbon inhaler programme in run-up to New York Climate Week.
article
UK life sciences sector: do you have the Vision for innovation?
Here, EPR explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
article
Achieving sustainable innovation with value-added medicines
The COVID-19 pandemic spotlighted drug repurposing as a key strategy to support traditional novel chemical entity development; yet repurposing is just one example of how off-patent molecules can be further developed to provide patients with more treatment options. Here, Arun Narayan, Chairman of the Value Added Medicines Sector Group at…
news
ICMRA set out recommendations for AI regulation in medicine
The ICRMA has set out recommendations to help regulators tackle the challenges posed by artificial intelligence (AI) in medicine.
news
Partnership to stabilise essential medicines supply with synthetic biology
Under a new collaboration, Antheia will use Ginkgo Bioworks’ cell programming platform to expand the capabilities of its whole-cell engineered pharmaceutical production pathways.
news
Drug price reduction could have no impact on future approvals, study finds
New research shows that drug price reductions under the US's H.R. 3 policy could have no impact on innovation in the pharmaceutical industry.
news
Advances in technology and manufacturing to promote plant-produced therapeutics uptake
Experts suggest investing in plant-based manufacturing systems could reduce costs and help scale up therapeutic protein manufacturing.
video
Supply of biosimilars and generics with Adrian van den Hoven, Medicines for Europe
In this interview, Adrian van den Hoven, Director General of Medicines for Europe, discusses all things supply of generic and biosimilar medicines for the continent. Also, in a bonus video, Adrian discusses challenges disrupting access to biosimilars and generics in Europe.
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-300x278.jpg)
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-e1624534468322.jpg)
news
GSK to focus on vaccines and specialty medicines in next decade
In an investor update, GlaxoSmithKline (GSK) revealed its plan to promote growth and performance over next ten years.
article
Becoming a Benefit Corporation and a certified B Corp: how sustainability practices may positively impact business operations
In this article, Giacomo Chiesi from Chiesi Group outlines why the company took steps to become Benefit Corporation and B Corp certified, how this status may impact business and the associated operations.
news
Pharma supply companies form the Alliance to Zero
The Alliance to Zero was founded by eight pharma/biotech supply companies to promote the transition of the pharma sector to net zero emissions.
article
The balancing act: accessibility and sustainability in packaging design
In an ageing society where people are living longer, often with debilitating conditions that require complex medical interventions, how might the way we experience and consume our drugs be changed? In this article, Echo’s Nick Dormon discusses some of the key challenges currently facing pharmaceutical packaging design, including accessibility and…
news
Amcor begins consumer trials of recyclable pharmaceutical blister packaging
Amcor’s new recyclable packaging solution, AmSky™, is expected to be available in the healthcare market by the second half of 2022.
news
New research could allow bioproduction of toxic compounds
A paper shows implementing riboregulated switchable feedback promoters enables cells to produce the precursors for potentially toxic chemotherapeutic and anti-malarial drugs.
